Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification

Clinical Cancer Research

Volumn 16, Issue 17, 2010, Pages 4353-4362

  De Brouwer, Sara ^a   De Preter, Katleen ^a   Kumps, Candy ^a   Zabrocki, Piotr ^b   Porcu, Michaël ^b   Westerhout, Ellen M ^d   Lakeman, Arjan ^d   Vandesompele, Jo ^a   Hoebeeck, Jasmien ^a   Van Maerken, Tom ^a   De Paepe, Anne ^a   Laureys, Geneviève ^a   Schulte, Johannes H ^f   Schramm, Alexander ^f   Van Den Broecke, Caroline ^a   Vermeulen, Joëlle ^a   Van Roy, Nadine ^a   Beiske, Klaus ^g   Renard, Marleen ^c   Noguera, Rosa ^h   Delattre, Olivier ⁱ   Janoueix Lerosey, Isabelle ⁱ   Kogner, Per ^j   Martinsson, Tommy ^k   Nakagawara, Akira ^l   Ohira, Miki ^l   Caron, Huib ^e   Eggert, Angelika ^f   Cools, Jan ^b   Versteeg, Rogier ^d   Speleman, Frank ^a   more..

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e EMMA CHILDREN S HOSPITAL   (Netherlands)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h UNIVERSITY OF VALENCIA   (Spain)

ⁱ INSTITUT CURIE   (France)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k UNIVERSITY OF GOTHENBURG   (Sweden)

^l CHIBA CANCER CENTER   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GLUTAMINE; LEUCINE; PHENYLALANINE;

ALK GENE; ARTICLE; CANCER SURVIVAL; CHROMOSOME 2P; GENE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE LOCUS; GENE MUTATION; HUMAN; HUMAN TISSUE; NEUROBLASTOMA; ONCOGENE MYC; PRIORITY JOURNAL; PROGNOSIS;

AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE FREQUENCY; HUMANS; KAPLAN-MEIER ESTIMATE; MUTATION; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES;

EID: 77956244494     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2660     Document Type: Article

References (23)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20.
2. Vandesompele J, Baudis M, De Preter K, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005;23:2280-99.
3. Michels E, Vandesompele J, De Preter K, et al. Array CGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer 2007;46:1098-108.
4. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27:1026-33.
5. Brodeur GM. Molecular basis for heterogeneity in human neuroblastomas. Eur J Cancer 1995;31A:505-10.
6. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455: 930-5.
7. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455: 975-8.
8. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971-4.
9. Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008;416:153-9.
10. Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967-70.
11. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
12. Menten B, Pattyn F, De Preter K, et al. array CGH base: an analysis platform for comparative genomic hybridization microarrays. BMC Bioinformatics 2005;6:124.
13. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-72.
14. Oberthuer A, Berthold F, Warnat P, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006;24:5070-8.
15. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999;86:349-63.
16. Lierman E, Michaux L, Beullens E, et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1- PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009;23:845-51.
17. Spitz R, Oberthuer A, Zapatka M, et al. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer 2006;45:1130-42.
18. Clifford SC, Lusher ME, Lindsey JC, et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 2006;5:2666-70.
19. Fattet S, Haberler C, Legoix P, et al. β-Catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 2009;218:86-94.
20. Murugan AK, Hong NT, Fukui Y, Munirajan AK, Tsuchida N. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int J Oncol 2008;32:101-11.
21. Zatkova A, Merk S, Wendehack M, et al. AML/MDS with 11q/MLL amplification show characteristic gene expression signature and interplay of DNA copy number changes. Genes Chromosomes Cancer 2009;48:510-20.
22. Hu G, Chong RA, Yang Q, et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 2009;15:9-20.
23. Passoni L, Longo L, Collini P, et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 2009;69:7338-46.